姚鸿，男，1989年出生，中国药科大学药物化学专业副教授，硕士生导师。2013年获中国药科大学基础药学理科基地班专业学士学位，2018年获中国药科大学药物化学专业博士学位，同年留校于药学院药化系做师资博士后，2021年晋升为副教授。

从事研究方向为药物化学、化学生物学及药物设计学，针对肿瘤、心脑血管疾病、神经退行性疾病开展创新小分子药物设计以及活性天然产物结构改造修饰研究。近年来以第一或通讯作者身份在Angewandte Chemie International Edition、Journal of Medicinal Chemistry、Acta Pharmaceutica Sinica B、European Journal of Medicinal Chemistry、Chemical Communications等专业领域国际著名刊物上发表SCI收录论文20余篇；获授权发明专利10余项，申请PCT 1项；参与获批新药临床批件1项，目前已进入临床II期；出版书籍3部，其中参与编写的《药物化学》入选“十四五”规划教材；作为课题负责人主持了国家及省部级科研项目7项，参与国家自然科学基金项目5项；主讲本科生课程《药物化学》、《药物化学实验》、《药物合成实验》，主讲研究生课程《天然产物新药研发选论》。

近5年部分代表性SCI论文（#表一作，*表通讯）：

1.      Shengnan Zhou#, Xiaotong Ze#, Dazhi Feng#, Lihua Liu, Yuning Shi, Minghui Yu, Lijuan Huang, Yunyue Wang, Hanlu Men, Jianbing Wu, Zhenwei Yuan, Mengze Zhou, Jinyi Xu*, Xinnan Li*, Hong Yao*. Identification of 6-Fluorine-Substituted Coumarin Analogues as POLRMT Inhibitors with High Potency and Safety for Treatment of Pancreatic Cancer. J. Med. Chem. 2024, doi: 10.1021/acs.jmedchem.4c01178.

2.     Chen He#, Junkai Liu#, Junda Li#, Hongyu Wu, Chenyang Jiao, Xiaotong Ze, Shengtao Xu*, Zheying Zhu, Wenjie Guo*, Jinyi Xu*, Hong Yao*. Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity. J. Med. Chem. 2024, 67, 9406–9430.

3.    Xinnan Li#, Xiaotong Ze, Shengnan Zhou, Zhaoxin Hu, Chen He, Yilin Jia, Lihua Liu, Tao Wang, Junda Li, Shengtao Xu, Dong-Hua Yang, Zhe-sheng Chen, Hequan Yao*, Jinyi Xu*, Hong Yao*. Discovery of a Novel, Potent, Orally Active, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase. J. Med. Chem. 2023, doi: 10.1021/acs.jmedchem.3c00058.

4.       Shaowen Xie#, Feiyan Zhan, Jingjie Zhu, Yuan Sun, Huajian Zhu, Jie Liu, Jian Chen, Zheying Zhu, Dong-Hua Yang, Zhe-Sheng Chen, Hong Yao*, Jinyi Xu*, Shengtao Xu* . Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation, Angew. Chem. Int. Ed. 2023, e2022172461.

5.       Dazhi Feng#, Lihua Liu, Yuqi Shi, Pian Du, Shengtao Xu*, Zheying Zhu, Jinyi Xu*, Hong Yao*. Current development of bicyclic peptides. Chin. Chem. Lett. 2023, 34: 108026.

6.       Shaowen Xie,# Jingjie Zhu,# Junda Li, Feiyan Zhan, Hong Yao,* Jinyi Xu,* Shengtao Xu*. Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation. J. Med. Chem. 2023, 66, 10917–10933.

7.       Yin Yuan,# Hong Yao,# Manzhen Zhou, Xiaoqian Ma, Yi Zhou, Jinyi Xu, Miaomiao Niu, Jun Yin*, Lufeng Zheng*, and Shengtao Xu*. Identification of a novel potent CYP4Z1 inhibitor attenuating the stemness of breast cancer cells through lead optimization. J. Med. Chem. 2022, 65, 15749–15769.

8.       Junkai Liu,# Shaowen Xie,# Xiao Shao, Songtao Xue, Pian Du, Hongyu Wu, Shengtao Xu, Zhe-Sheng Chen, Dong-Hua Yang, Jinyi Xu*, Hong Yao* ; Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin. Eur. J. Med. Chem. 2022, 231: 114155.

9.       Hongyu Wu,# Hong Yao,#,* Chen He, Yilin Jia, Zheying Zhu, Shengtao Xu*, Dohong Li, Jinyi Xu*. Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. Acta Pharm. Sin. B 2022, 12: 3548-3566.

10.    Xiang Ni#, Chen He#, Yilin Jia, Xiuyuan Wu, Kunyu Zhou, Shengtao Xu, Jinyi Xu *, Hong Yao *. Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin. Bioorg. Med. Chem. 2022,72, 116977.

11.    Hong Yao,# Giuseppe Uras,# Pengfei  Zhang,# Shengtao Xu, Ying Yin, Jie Liu, Shuai Qin, Xinuo Li, Stephanie  Allen, Renren Bai, Qi Gong, Haiyan Zhang,* Zheying Zhu,* and Jinyi Xu*.  Discovery of Novel Tacrine−Pyrimidone Hybrids as Potent Dual AChE/GSK‑3  Inhibitors for the Treatment of Alzheimer’s Disease. J. Med. Chem. 2021, 64, 7483−7506.

12.     Shengtao Xu,# Hong Yao,# Yangyi Qiu,# Manzhen Zhou, Dahong Li,* Liang Wu,* Dong-Hua Yang, Zhe-Sheng Chen, and Jinyi Xu*. Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. J. Med. Chem. 2021, 64, 17346−17365.

13.     Hong Yao#,  Shaowen Xie, Xiaoqian Ma, Junkai Liu, Hongyu Wu, Aijun Lin, Hequan Yao,  Dahong Li, Shengtao Xu*, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu*.  Identification of a Potent Oridonin Analogue for Treatment of  Triple-Negative Breast Cancer. J. Med. Chem. 2020, 63, 8157−8178.

14.    Junkai Liu#, Hong Yao#, Xinnan Li, Hongyu Wu, Aijun Lin, Hequan Yao, Jinyi Xu*, Shengtao Xu*. Organocatalytic 1,5-trifluoromethylthio-sulfonylation of vinylcyclopropane mediated by visible light in the water phase. Org. Chem. Front. 2020,7, 1314-1320.

15.     Hong Yao^#, Shanshan Luo^#,  Junkai Liu, Shaowen Xie, Yanpeng Liu, Jinyi Xu*, Zheying Zhu, Shengtao  Xu*. Controllable Thioester-based Hydrogen Sulfide Slow-Releasing Donors  as Cardioprotective Agents. Chem. Commun., 2019, 55, 6193-6196.